Digestive System Diseases

The department is conducting studies on metastatic colorectal cancer and advanced rectal cancer, aiming to improve treatment outcomes and organ preservation.

  • Trifluridine/tipiracil plus panitumumab versus bevacizumab in first‑line metastatic colorectal cancer
  • Post‑resection/ablation chemotherapy for metastatic colorectal cancer
  • Short‑course radiotherapy versus chemoradiotherapy with selective organ preservation in high‑risk rectal cancer
  • Fruquintinib combined with Tislelizumab in microsatellite stable metastatic colorectal cancer without liver metastases

HELIOS Klinikum Emil von Behring hosts 29 active trials with 14 investigators, reflecting a strong focus on gastrointestinal oncology.

Immune System Diseases

Research includes innovative immunotherapies for lung and kidney cancers, evaluating combinations that may enhance immune response.

  • Pembrolizumab plus axitinib versus sunitinib in renal cell carcinoma
  • Durvalumab combined with domvanalimab after chemoradiation in unresectable stage III NSCLC
  • Nivolumab and ipilimumab with chemotherapy versus chemotherapy alone in stage IV NSCLC
  • LY3537982 dose‑optimization study in combination with pembrolizumab

These trials aim to test new immune‑modulating agents and assess their safety and efficacy in patients with advanced malignancies.

Neoplasms

The oncology unit focuses on a broad range of solid tumours, from lung to mesothelioma, seeking novel targeted and combination therapies.

  • ALK‑positive NSCLC studies with brigatinib, alectinib, and NVL‑655
  • EGFR‑mutated NSCLC treated with amivantamab plus lazertinib versus osimertinib
  • KRAS G12C‑mutant NSCLC evaluated with divarasib, sotorasib, adagrasib, and pembrolizumab combinations
  • Unresectable pleural mesothelioma trial comparing volrustomig plus carboplatin/pemetrexed to standard regimens

The site’s multidisciplinary team is dedicated to advancing cancer care through these diverse investigational programs.

Respiratory Tract Diseases

Studies target various lung conditions, including several subtypes of non‑small cell lung cancer and small‑cell lung cancer, to improve survival and disease control.

  • Dato‑DXd monotherapy versus chemotherapy in advanced NSCLC after osimertinib
  • Lurbinectedin plus atezolizumab maintenance therapy in extensive‑stage small‑cell lung cancer
  • Entrectinib versus crizotinib in ROS1‑rearranged NSCLC with CNS metastases
  • Inhalation therapy trial for adult bronchiectasis patients with new Pseudomonas aeruginosa infection

These trials evaluate both targeted agents and novel delivery methods to address unmet needs in respiratory oncology.

Skin and Connective Tissue Diseases

Research includes therapeutic approaches for chronic wounds and inflammatory lung disease, focusing on healing and disease modulation.

  • Topical allo‑APZ2‑CVU for therapy‑resistant chronic venous ulcers
  • Namilumab evaluation in chronic pulmonary sarcoidosis
  • Stem‑cell therapy investigation for long‑term non‑healing venous leg ulcers
  • ColiFin® therapy versus standard of care for airway colonization in bronchiectasis

The aim is to enhance wound closure rates and reduce inflammatory activity, offering new options for patients with persistent skin and connective tissue disorders.

Environment and Public Health

The institution also addresses public‑health aspects by exploring infection control and environmental factors influencing disease outcomes.

  • Evaluation of ColiFin® therapy to achieve airway culture negativity in bronchiectasis
  • Assessment of infection‑related outcomes in chronic lung disease trials
  • Monitoring of safety signals across multiple oncology studies to inform public health policy
  • Integration of real‑world data for environmental exposure analysis in cancer patients

These initiatives support broader health strategies and aim to translate clinical findings into community‑wide benefits.